SARS-CoV-2-IN-109

SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC50=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC50=17.0 μM) . The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM[1].

Product Specifications

UNSPSC

12352005

Target

SARS-CoV

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

[H][C@@]12C3=CC=CC=C3C=CN1[C@](C(C4=CC=CC=C4)=O)([H])[C@]5([H])C6=C(C=CC=C6)C=CN5[C@@]2([H])C(C7=CC=CC=C7)=O

Molecular Formula

C34H26N2O2

Molecular Weight

494.58

References & Citations

[1]Palla S, et al. Green Synthesis of Tetrahydropyrazino[2,1-a:5,4-a']diisoquinolines as SARS-CoV-2 Entry Inhibitors. ACS Omega. 2024 Dec 20;10 (1) :1164-1176.